IP Library Granted Patent US 9,925,257
Granted Patent B2
US 9,925,257 · App. 14/604,215 · Granted Mar 27, 2018

Vaccine and therapeutic delivery system

Inventors: Antonio Campos-Neto (Westborough, MA); Mark Cayabyab (San Jose, CA); Margaret Duncan (Brookline, MA)
Assignee: Forsyth Dental Infirmary for Children
A61K39/21A61K39/04A61K39/08A61K39/12A61K45/06C07K14/005C07K14/315C07K14/33C07K14/35A61K2039/523A61K2039/541A61K2039/545A61K2039/58C07K2319/02C07K2319/21C07K2319/40C07K2319/55C12N9/2402C12N2740/15022C12N2740/15033C12N2740/16033C12N2740/16122C12N2740/16134C12N2740/16171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,925,257
App. No.
14/604,215
Granted
Mar 27, 2018
Kind
B2
Abstract

The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

Claims (8)

1. An integrally transformed non-pathogenic, commensal bacterium that expresses a synthetic nucleic acid molecule encoding a foreign fusion polypeptide comprising a C. difficile antigen and a signal polypeptide therein, wherein the synthetic nucleic acid molecule is stably integrated into genomic DNA of the bacterium, wherein the bacterium is Streptococcus mitis , and wherein the synthetic nucleic acid molecule comprises a TcdA/TcdB fusion construct having SEQ ID NO:81.

2. The integrally transformed non-pathogenic, commensal bacterium of claim 1 , wherein the foreign fusion polypeptide elicits an immunogenic response in an individual.

3. The integrally transformed non-pathogenic, commensal bacterium of claim 1 , wherein the foreign fusion polypeptide is expressed in the cytoplasm, in the cell membrane or cell wall, or exports to the cell surface of the bacterium.

4. The integrally transformed non-pathogenic, commensal bacterium of claim 3 , wherein the signal polypeptide is selected from the group consisting of: serine-rich GspB homologue and the pullulanase polypeptide.

5. The integrally transformed non-pathogenic, commensal bacterium of claim 1 , wherein the TcdA/TcdB fusion construct encodes an amino acid sequence comprising SEQ ID NO: 82.

6. The integrally transformed non-pathogenic, commensal bacterium of claim 5 , wherein the TcdA/TcdB fusion construct is inserted into a gene that encodes a pullulanase polypeptide.

7. The foreign fusion polypeptide expressed by the integrally transformed non-pathogenic, commensal bacterium of claim 1 .

8. A method of delivering a foreign fusion polypeptide to an individual comprising: contacting the integrally transformed non-pathogenic, commensal bacterium of claim 1 with tissue of the oral cavity or upper respiratory tract of the individual in an amount sufficient for colonization of said bacterium.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 18, 2018
From: FORSYTH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046377/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2018
From: CAMPOS-NETO, ANTONIO; CAYABYAB, MARK; DUNCAN, MARGARET
To: FORSYTH DENTAL INFIRMARY FOR CHILDREN
Reel/Frame 045135/0729 →
Continuity (3)
Continuation In Part 13624146 · Sep 21, 2012
Provisional Application 61538346 · Sep 23, 2011
Related Publication 20160045591A1 · Feb 18, 2016